Prospective Grant of an Exclusive Patent License: High ASS1 Expressing Tumors Embody a Purine Rich Genomic Signature and Sensitivity to Purine Depletion, 36567 [2021-14681]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person. Any
member of the public may submit written
comments no later than 15 days after the
meeting.
Information is also available on the
Institute’s/Center’s home page: https://
www.nccih.nih.gov/news/events/advisorycouncil-78th-meeting, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: July 7, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–14739 Filed 7–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: High ASS1 Expressing
Tumors Embody a Purine Rich
Genomic Signature and Sensitivity to
Purine Depletion
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute
(NCI), an institute of the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive,
sublicensable patent license to Yeda
Research & Development Co, Ltd
(‘‘YEDA’’), the technology transfer
company of the Weizmann Institute of
Science, a non-profit research
institution located in Rehovot, Israel for
NCI’s rights to the patent applications
listed in the Supplementary Information
section of this notice.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before July 27, 2021 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Kevin W. Chang, Ph.D.,
Senior Licensing and Patenting Manager
at Telephone: (240)–276–6910 or at
Email: changke@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:26 Jul 09, 2021
Jkt 253001
Intellectual Property
The following and all continuing U.S.
and foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to YEDA: PCT Patent
Application PCT/IL2020/050708, filed
June 24, 2020 and entitled ‘‘High ASS1
Expressing Tumors Embody A Purine
Rich Genomic Signature And Sensitivity
To Purine Depletion’’ [HHS Reference
No. E–210–2020–0–PCT–01].
The patent rights in these inventions
have been assigned to the Government
of the United States of America and
YEDA. The prospective license will be
for the purpose of consolidating the
patent rights to YEDA, one of the coowners of said rights, for commercial
development and marketing.
Consolidation of these co-owned rights
is intended to expedite development of
the invention, consistent with the goals
of the Bayh-Dole Act codified as 35
U.S.C. 200–212.
The prospective patent license will be
worldwide, exclusive, and may be
limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by YEDA will be
subject to the provisions of 37 CFR parts
401 and 404.
This technology discloses methods of
treating a high argininosuccinate
synthase (ASS1) expressing solid tumor
with a combination of a purine synthase
inhibitor or an agent that increases the
pyrimidine to purine ratio in a cell, and
an immune-modulating drug, such as a
checkpoint inhibitor.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
include terms for the sharing of royalty
income with NCI from commercial
sublicenses of the patent rights. The
prospective exclusive license may be
granted unless within fifteen (15) days
from the date of this published notice,
the National Cancer Institute receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license
that are timely filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
patent license. In response to this
Notice, the public may file comments or
objections. Comments and objections,
other than those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
36567
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: July 6, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2021–14681 Filed 7–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice To Announce Request for
Information (RFI) Inviting Input on the
ICCFASD 2022–2026 Strategic Plan
Outline
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Interagency Coordinating
Committee on Fetal Alcohol Spectrum
Disorders (ICCFASD) is developing an
updated strategic plan to guide its
efforts over the next five years. As
sponsor and chair of the ICCFASD, the
National Institute on Alcohol Abuse and
Alcoholism (NIAAA) will be issuing a
Request for Information to seek
comments on the draft outline of the
ICCFASD’s 2022–2026 Strategic Plan
from diverse stakeholders, including
scientific experts, health care providers,
patients and family members, advocacy
groups, other federal agencies, and nongovernmental scientific, professional,
and healthcare organizations.
DATES: Comments must be received by
August 31, 2021, to ensure
consideration. Responses will be
reviewed by ICCFASD members and
considered during the development of
the 2022–2026 Strategic Plan.
ADDRESSES: To view and comment on
the strategic plan outline, please visit
our online response form: RFI online
response form.
FOR FURTHER INFORMATION CONTACT:
Tatiana Balachova, ICCFASD Executive
Secretary, National Institute on Alcohol
Abuse and Alcoholism, NIH, 6700B
Rockledge Drive, Bethesda, MD 20817.
Phone: 301–443–5726, Email: NIAAAICCFASD@mail.nih.gov.
SUPPLEMENTARY INFORMATION: In
accordance with the 21st Century Cures
Act, NIH institutes are required to
SUMMARY:
E:\FR\FM\12JYN1.SGM
12JYN1
]]>Agencies
[Federal Register Volume 86, Number 130 (Monday, July 12, 2021)]
[Notices]
[Page 36567]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-14681]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: High ASS1
Expressing Tumors Embody a Purine Rich Genomic Signature and
Sensitivity to Purine Depletion
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute (NCI), an institute of the
National Institutes of Health, Department of Health and Human Services,
is contemplating the grant of an exclusive, sublicensable patent
license to Yeda Research & Development Co, Ltd (``YEDA''), the
technology transfer company of the Weizmann Institute of Science, a
non-profit research institution located in Rehovot, Israel for NCI's
rights to the patent applications listed in the Supplementary
Information section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before July 27, 2021 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Kevin W. Chang, Ph.D., Senior Licensing and
Patenting Manager at Telephone: (240)-276-6910 or at Email:
[email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
The following and all continuing U.S. and foreign patents/patent
applications thereof are the intellectual properties to be licensed
under the prospective agreement to YEDA: PCT Patent Application PCT/
IL2020/050708, filed June 24, 2020 and entitled ``High ASS1 Expressing
Tumors Embody A Purine Rich Genomic Signature And Sensitivity To Purine
Depletion'' [HHS Reference No. E-210-2020-0-PCT-01].
The patent rights in these inventions have been assigned to the
Government of the United States of America and YEDA. The prospective
license will be for the purpose of consolidating the patent rights to
YEDA, one of the co-owners of said rights, for commercial development
and marketing. Consolidation of these co-owned rights is intended to
expedite development of the invention, consistent with the goals of the
Bayh-Dole Act codified as 35 U.S.C. 200-212.
The prospective patent license will be worldwide, exclusive, and
may be limited to those fields of use commensurate in scope with the
patent rights. It will be sublicensable, and any sublicenses granted by
YEDA will be subject to the provisions of 37 CFR parts 401 and 404.
This technology discloses methods of treating a high
argininosuccinate synthase (ASS1) expressing solid tumor with a
combination of a purine synthase inhibitor or an agent that increases
the pyrimidine to purine ratio in a cell, and an immune-modulating
drug, such as a checkpoint inhibitor.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will include terms for the
sharing of royalty income with NCI from commercial sublicenses of the
patent rights. The prospective exclusive license may be granted unless
within fifteen (15) days from the date of this published notice, the
National Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license that are timely filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive patent license. In response to this Notice,
the public may file comments or objections. Comments and objections,
other than those in the form of a license application, will not be
treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: July 6, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2021-14681 Filed 7-9-21; 8:45 am]
BILLING CODE 4140-01-P
